Allergic asthma is a chronic, airway inflammatory disease in which exposure to allergens cause intermittent attacks of breathlessness, airway hyperreactivity, wheezing and cough. Allergic asthma has been called a "syndrome" resulting from a complex interplay between genetic and environmental factors. Worldwide more than 300 million individuals are affected by this disease, and in the US alone it is estimated that more than 35 million people, mostly children, suffer from asthma. Although animal models, linkage analyses and genome-wide association studies have identified numerous candidate genes, a solid definition of allergic asthma has not yet emerged; however, such studies have contributed to our understanding of the multiple pathways to this syndrome. In contrast to the animal models in which Thelper 2 (T H 2) cell response is the dominant feature, in human asthma as an initial exposure to allergen results in T H 2-dependent stimulation of immune response that mediates the production of immunoglobulin E (IgE) and cytokines. Re-exposure to allergen then activates mast cells, which release mediators such as histamines and leukotrienes that recruit other cells including T H 2 cells, which mediate the inflammatory response in the lungs. In this review, we discuss the current understanding of how associated genetic and environmental factors increase the complexity of allergic asthma and the challenges allergic asthma poses for the development of novel approaches to effective treatment and prevention.
human disease. In contrast to the mouse models in which T-helper 2 (T H 2) 1 response is the dominant feature, the pathogenesis of human allergic asthma involves an initial exposure of an allergen mediating T H 2-dependent stimulation of an immune response resulting in the production of IgE and cytokines. Repeated exposure to allergen then activates mast cells, which release mediators that facilitate recruitment of other cell types including T H 2 cells that mediate the inflammatory response in the airways (reviewed in 8). Thus, while T H 2 axis plays a critical role in initiating the IgE response and airway inflammation, the presence of an allergen-specific IgE does not necessarily culminate in asthma. In this minireview we shall discuss what makes allergic asthma a complex disease in which genetic and environmental factors merge to cause pathogenesis.
Current understanding of allergic asthma pathogenesis. While several types of asthma have been recognized clinically, allergic asthma is the most common form of the disease (reviewed in 9). In susceptible individuals, the initiation of allergen sensitivity occurs at the mucosal surfaces where environmental allergens meet the mucosal epithelia. The interaction of inhaled allergen(s) with sensitized immune cells in the airway results in allergic asthma. Allergic rhinitis, atopic dermatitis and asthma, which constitute atopic conditions, occur in individuals with markedly increased levels of IgE antibodies (10) . The expression of high-(FcεRI) and low-affinity (FcεRII; CD23) IgE receptors, occur in a wide variety of cell types including the dendritic cells (DCs) and B cells (Fig. 1a) . IgE bound to these receptors on B cells and DCs facilitates the uptake of allergen by these cells, promoting allergen presentation to T cells, which mediate secondary immune responses. The majority of IgE is bound by FcεRI on mast cells as well as basophils, and IgE-bound FcεRI crosslinking by specific antigen mediate the release of inflammatory mediators (eg. histamine and leukotrienes) by mast cells (Fig.1b) leading to the inflammatory response.
The regulation of IgE production and its relationship to the development of T H 2 cells that drive IgE responses have been reviewed (8) . Enhanced tendency toward airway hyper-reactivity (AHR) culminating in bronchial smooth muscle contraction, characteristically found in patients with asthma, is often linked to high IgE levels (11) . Moreover, it has been reported that in cohorts of children with asthma and physiologic evidence of AHR, high serum levels of IgE are detectable (12) . While both in animal models as well as in humans some component of asthmatic pathophysiology, especially acute reactions to allergen, may be IgE-mediated, the other features of this disease may arise independently of IgE. Thus, in atopic families inhalation of allergens and subsequent production of IgE are associated with predisposition to allergic asthma. Further, it is likely that IgE participates in triggering mast cell-mediated acute-and late-phase airflow obstruction (10) . Allergen exposure also triggers activation of the bone marrow-derived and non-bone marrow-derived cells of the innate immune system, which eventually leads to the secretion of various cytokines (3) . The recruitment of antigen-processing cells, most likely the monocyte-derived dendritic cells (DCs), initiates the pathway to inflammation. Recently, it has been reported that basophils may also be involved in certain situations. Moreover, it has been reported that in the airways of patients with asthma and especially in those patients suffering from allergic asthma, allergenspecific T H 2 cells are readily detectable (13) . Recently, several excellent reviews have been published on T H 2 cell differentiation (14) (15) (16) (17) , which the readers may consider for detail knowledge on this subject. The T H 2 cells secrete cytokines, which promote the synthesis of allergen-specific immunoglobulin E (IgE). These cytokines also promote presentation of antigens (allergens) to CD4 + T cells, which facilitates both DCs as well as the T-cells to elicit T H 2 cell responses (18, 19) . In addition, activated T H 2 cells also secrete the cytokines, interleukin-5 (IL-5), IL-9 and IL-13, which facilitate the recruitment of eosinophils and promote growth of mast cells, respectively and ultimately, stimulating AHR, characteristically found in asthma (9, 20 Fig. 2 , the pathways that lead to allergic asthma are summarized.
Genetic susceptibility to allergy and asthma. As stated earlier in this review, asthma and asthma-related syndromes are complex diseases in which interplay of strong genetic and environmental components leads to pathogenesis (reviewed in 7, 26-32). It has been well known that many individuals are predisposed to developing allergic reactions to substances that do not generally elicit immune response. These atopic individuals are thought to be genetically predisposed to develop hypersensitivity to commonly used substances such as pollens, antibiotics and perfumes. Numerous studies have shown that atopy is familial in nature. Elevated levels of IgE have been detected in patients with allergic diseases (7) and IgE production is tightly controlled. Recently, it has been reported that NF-IL3, a transcriptional regulator, may control IgE production (33) . The early studies have reported the prevalence of allergic disease in first degree relatives of affected individuals (34, 35) . Subsequently, studies in monozygotic and dizygotic twins have shown a positive correlation with regard to allergic disease traits such total serum IgE levels, methacholine sensitivity in the lungs and skin test results being two fold higher among monozygotic twins than dizygotic twins. Moreover, children of asthmatic parents are found to be more likely to develop asthma than those from parents without any history of atopy. Studies on atopic disease in human and animal populations have facilitated the identification of susceptibility genes encoding class II MHC, Fc€RI-ß, RANTES, IL-4 receptor alpha, ß-adrenergic receptor, T-cell receptor alpha and mast cell chymase. Further, evidence has been amassed to suggest that genetic loci on human chromosome 5, 6 and 11 are likely to harbor atopy genes. A thorough review of the molecular genetics of allergic diseases provides insight into the complexity of the atopic disease and why the identification of specific atopy genes remains challenging (reviewed in 36).
During the past decade knowledge in asthma genetics has progressed significantly, and several genes or gene loci associated with asthma-and/or atopy-related syndromes have been identified. However, most of these genes have only modest effects and the majority of these genes are not systematically tested to determine whether the results are replicable in different populations. Several excellent reviews on the genetics of allergy and asthma have been published (2, 7, (26) (27) (28) (29) (30) (31) (32) and the readers interested in obtaining in-depth knowledge in this area may consider perusing these articles. In this review, we shall discuss only those genes that have shown functional and immunological links for susceptibility to asthma and allergy. In general, asthma susceptibility genes are classified into 4 main groups (reviewed in 7, 26, 32): (i) the innate immunity and immunoregulatory genes, (ii) genes associated with T H 2 cell differentiation and effector functions, (iii) genes associated with mucosal immunity and epithelial biology and (iv) genes that are linked to lung function, airway remodeling and severity of the disease (7, 26, 32) . The interactions among the genes in the first three groups and those identified by positional cloning have been reviewed in detail (32) and are summarized in Fig. 3 . The genes included in the first group are discovered through association studies and are thought to be involved with triggering the immune response and stimulating differentiation of CD4 + T helper (T H )-cells. and PDE4D that are associated with atopy and asthma have been identified via association studies and positional cloning (37) . The genes encoding T cell immunoglobulin domain, mucin-like domain (TIM) family (38, 39) as well as the disintegrin and metalloproteinase domain 33 (ADAM33) on human chromosome 20p13 are associated with asthma and AHR (40) . In addition to association studies and positional cloning, genome-wide association studies have also been carried out to identify asthma-susceptibility genes (27) (28) (29) (30) (31) (32) . This method utilizes single nucleotide polymorphisms (SNPs) for screening across the whole genome to identify novel disease susceptibility genes without the bias of prior knowledge. However, due to the lack of biological correlates, in some instances the genes identified by this method have raised questions about the true relevance of these genes to the disease (32) . Recently, three independent reports have been published (41) (42) (43) in which asthma susceptibility genes have been identified utilizing knowledge from asthma genetics as well as asthma biology. As stated earlier in this discussion, most of the identified genes have not been rigorously tested as to whether the results are replicable in different populations.
Gene expression in allergic airway inflammation and allergic asthma Our knowledge of allergen-mediated inflammatory response in the airways has been greatly advanced by the availability of mouse models of allergic asthma. The hallmark of allergic asthma immunopathology is the infiltration of the airways by eosinophils and T H 2 cells (44). Recruitment of T H 2 cells to the lungs mediates the development of eosinophilic inflammation and AHR (9) . Mice can be sensitized to foreign antigens (allergens) including ovalbumin (OVA) by introducing this antigen combined with adjuvant such as alum (45) . Immunization with OVA in alum causes IgE and IgG1 production. When subjected to repeated exposure to the allergen, the OVA-sensitized mice develop airway eosinophilia, hyperplasia of mucous secreting goblet cells and AHR, which are some of the characteristic features of allergic asthma. When these changes occur chronically they lead to airway remodeling (46) , which is also characteristically found in allergic asthma. It should be noted that while allergen specific T H 2 cells can be induced in mice (26) and in non-human primates (47) , there are substantial differences between human and animal models of allergic airway disease (reviewed in 48).
To characterize gene expression in allergic airway inflammation, gene micro-arrays have been used (49, 50) . The profiling of gene expression by microarray has been used to characterize asthma related genes in both humans and mice (Table 1 in 
The allergen-induced responses in allergic asthma are driven predominantly by effector T cells, mostly by T H 2 cells, which are regulated by regulatory T (T reg ) cells and thus, both T H 2 and Treg cells are studied by gene expression profiling. Microarray analyses of T H 1 and T H 2 cells differentiated from cord blood T lymphocytes have allowed Rogge et al. (52) to demonstrate that out of 6000 genes studies 215 were differentially expressed among the two T cell subsets. Studies with CD4+ T cells from patients with atopy or allergic asthma activated in vitro have shown differential gene expression in the two types of allergic disorders (53) . Similar studies have facilitated discovery of a family of genes called Ephrins, which are associated with allergic asthma pathology (54) . Gene expression profiling using T reg cells facilitated the discovery that IL-10 and inducible costimulator (ICOS) promote regulation of effector cells (55) . Other investigations related to allergicinflammation provide gene expression profiles using eosinophils (56) and basophils (57) . Similar studies were conducted on a transcriptome level to determine the differentiation of DCs by contact allergens that can also trigger airway inflammation and AHR (58) . It should be noted, however, that while a vast amount of data from investigations on gene-expression profiles have been amassed, only a small portion of this information has been used to advance our knowledge on the molecular mechanism(s) of allergic asthma. This may be due to the fact that the roles of numerous transcription factors, signaling molecules and enzymes in allergic asthma have not yet been fully elucidated. Thus, many recent studies have focused on gene expression studies that could be associated with specific functions such as chemotaxis, inflammation and cytokine regulation.
One of the puzzling phenomena in allergic diseases, especially allergic asthma, is that while our airways are exposed to myriads of allergens on a daily basis, only a small percentage of the world's population suffers from allergic asthma. Thus, although the incidence of allergic asthma continues to rise, the majority of the world's population manages to avert allergic inflammatory diseases including allergic asthma. Therefore, it is likely that some genes constitutively expressed in the airways maintain homeostasis in the mammalian respiratory system that suppresses the allergen-mediated inflammatory response. An example of such a gene is uteroglobin (UG; 59) also known as Clara cell 10 or CC10kDa protein (60) . UG is a secretory protein, which manifests immunomodulatory, anti-chemotactic and anti-inflammatory properties (reviewed in 61). This protein is produced and secreted by the mucosal epithelia of all organs that communicate with the external environment. Moreover, it is constitutively expressed at a high level in the airway epithelial cells and UG-knockout (UG-KO) mice (62) develop increased susceptibility to allergen-induced airway inflammation. Recently, it has been reported that UG suppresses allergen (OVA)-induced airway inflammatory response by blocking prostaglandin D 2 (PGD 2 ) receptor-mediated function (63) . This protein has also been reported to inhibit T H 2-cell differentiation by acting on DCs (64, 65) . Interestingly, human orthologs of murine squamous cell carcinoma antigen-2 (SCCA-2/serpinb3a), a serine protease inhibitor associated with allergic inflammation, are overexpressed in the airways of asthma patients (reviewed in 66). Most interestingly, SCCA2 is expressed at high levels in the airways of UG-KO mice and is further augmented by allergen challenge; treatment of these mice with recombinant UG abrogated the allergeninduced elevation of SCCA gene expression (67) . Further, UG also inhibits allergeninduced T H 2 differentiation by downregulating the expression of serum amyloid A (SAA) and suppressor of cytokine signaling-3 (SOCS-3) gene (68) , which play critical regulatory roles in the initiation and maintenance of T H 2 mediated allergic airway inflammatory response (69) .
Studies in humans and in mouse model of allergic asthma have shown that TIM family of genes is associated with allergen-mediated diseases (38) . It has also been reported that monoclonal antibodies directed against mouse TIM-1 suppresses allergen-mediated inflammation in various organs including the lungs (70) (71) (72) (73) . More recently, using a humanized mouse model generated by injecting peripheral blood monocytes from asthma patients into immunocompromised severe combined immunodeficient mice, Sonar et al. have reported that monoclonal antibody against TIM-1 suppressed the production of proinflammatory T H 2 cytokines and prevented AHR (74) . These results have clearly demonstrated that TIM-1 pathway plays a critical role in allergic asthma and more importantly, antagonizing TIM-1 may provide therapeutic benefit to patients with allergic asthma and other immune-mediated inflammatory disorders.
Most intriguingly, the discovery of a mutant mouse strain called "flacky tail" in the Jackson Laboratory in 1958 and that reported in 1972 (75) may provide new insight into the pathogenesis of atopic dermatitis (eczema) and allergic asthma. Recently, Fallon and coworkers (76) have reported that flacky tail mice carry homozygous frameshift mutation in the gene encoding filaggrin, a large structural protein that facilitates terminal differentiation of the epidermis and forms skin barrier. Interestingly, this mutation closely resembles FLG variants in humans that cause icthyosis vulgaris (77), a skin disorder, which is a genetic risk for atopic dermatititis and associated allergic asthma (78, 79) . While this association between FLG mutation and atopic dermatitis is strong, it has been reported that nearly 40% of individuals carrying null mutation in this gene do not develop the skin disease (80) . This may suggest that both genetic and environmental modifiers may be involved in the pathogenesis of atopic dermatitis and associated allergic asthma (81) .
Environmental factors interacting with genetic factors in allergic asthma. As discussed earlier, while allergic diseases such as allergic asthma have predisposing genetic factors, the interaction of environmental factors in the pathogenesis of allergic diseases are compelling. Environmental factors (both ingested and inhaled) have been suggested to contribute to allergic-asthma pathogenesis (reviewed in 27). Examples of the environmental factors include air pollutants, respiratory viruses, tobacco smoke, endotoxin, allergens in the air and diet. Occupational environment can also trigger asthma in genetically susceptible individuals (82) . Thus, studies on geneenvironment interactions may advance our understanding of the complex mechanism(s) of allergic asthma (83) (84) (85) (86) . Genes encoding pattern-recognition receptors, such as Tolllike receptor-4 (TLR4) and CD14 are reported to recognize and clear bacterial endotoxin, LPS, and single nucleotide polymorphisms (SNPs) of these genes may initiate asthma pathology in early development (27) . Atopic individuals who carry SNPs in the CD14, TLR4 and other TLR genes have been found to modify the risk of asthma susceptibility (87) . Similarly, SNPs in the TGF-β1 (88), IL-10 (89), DCassociated nuclear protein-1 (DCNP1) (90), inflammatory cytokines and enzymes (91) have been reported to alter geneenvironment interaction in allergic asthma. Polymorphisms in the TNF-α gene (92) , and the risk of childhood asthma in relation to environmental tobacco smoke and SNPs in the q21 region of human chromosome 17 (93) , also point to gene-environment interaction.
The subject of geneenvironment interactions in the pathogenesis of respiratory diseases has recently been reviewed (7, 94, 95) .
Concluding Remarks and Perspectives. During the past decade major advances have been made in our understanding of the immune mechanisms of allergic diseases including allergic asthma. However, these advances have not yet resulted in the development of effective new therapeutic approaches. It is possible that our knowledge of interacting genetic and environmental factors affecting pathogenesis of this disease remains incomplete. Thus, further advance in the genetics of allergic asthma and the interaction of candidate asthma genes with environmental factors may facilitate the development of novel therapies. One of the puzzling aspects of allergic asthma pathogenesis is the fact that despite our exposure to myriads of antigens (allergens) only a relatively small portion of the total human population suffers from allergic diseases. Recent efforts to treat allergic diseases have been focused on the application of biological agents such as monoclonal antibodies to target specific cytokines and cell surface proteins associated with allergic inflammatory response.
For example, it has been demonstrated that blocking TM-1 by using specific monoclonal antibodies may prevent allergic inflammatory responses. These are welcome developments although we should be cautious that these therapeutic approaches do not compromise the many facets of immune responses (some of which are poorly understood) that are essential for maintaining homeostasis in the human body. _______________ 1 The abbreviations used are : T H 2, T-helper 2; IgE, immunoglobulin E; DCs., Dendritic cells ; ADAM33, a disintegrin and metalloproteinase domain 33; AHR, airway hyper-responsiveness; APC, antigen presenting cell; CC16, Clara cell-specific 16 kDa protein (also known as SCGB1A1); CCL, CC-chemokine ligand; CD14, monocyte differentiation antigen 14; COL29A1, Collagen type XXIX alpha-1 (also called COL6A5, Collagen alpha-5 (VI) chain); DCNP1, dendritic cell associated nuclear protein-1; DEFB1, defensin 1; DPP10, dipeptidyl peptidase 10; FCERIB, high-affinity Fc receptor for IgE -chain; FLG, filaggrin; GATA3, GATA-binding protein 3; GPRA, G-protein-coupled receptor for asthma susceptibility (also known as NPSR1 and GPRA154); IL, interleukin; IL4RA, interleukin-4 receptor ( -chain); IL5RA, interleukin 5 receptor ( -chain); IRAKM, interleukin-1 receptor-associated kinase 1; NOD, nucleotide-binding, oligomerization-domain-containing; PGD 2 R, prostaglandin D 2 receptor; PGE 2 R, prostaglandin E 2 receptor; PHF11, plant homeodomain finger protein 11; SCCA, squamous cell carcinoma antigen; SOCS-3, suppressor of cytokine signaling-3; SPINK5, serine protease inhibitor, Kazal-type, 5; STAT, signal transducer and activator of transcription; TBX21, T-box 21 (also known as T-bet); TCR, T-cell receptor; TGFb1, transforming growth factor-1; TLR, Toll-like receptor; T Reg , regulatory T cell; UG, uteroglobin. This group includes genes encoding CD14, TLR2, TLR4, TLR6, TLR10, NOD1 and NOD2, which are known as pattern recognition receptors. This group also includes those that encode immunoregulatory cytokines such as IL10 and TGFß1, the transcription factor STAT3, antigen presentation facilitator genes such as HLA-DR, HLA-DQ and HLA-DP alleles and the prostaglandin receptor, PGER2. Genes in group (B) includes GATA3, TBX21, IL4, IL13, IL4RA, FCER1B, IL5, IL5RA, STAT6 and IL12B, which regulate T H 2-cell differentiation and effector functions. The third group (C) includes CCL5, CCL11, CCL24 and CCL26 (chemokines), DEFB1 (antimicrobial peptides), CC16 also called UG (anti-inflammatory protein) and SPINK5 and FLG (factors responsible for maintaining epithelial-cell barrier). Positional-cloning method has been used to identify the following genes expressed in the epithelia and smooth muscles: ADAM33, COL29A1, DPP10, GPRA, HLA-G, IRAKM and PHF11 (26) . 
